Rocket Pharmaceuticals Inc expected to post a loss of 68 cents a share - Earnings Preview

Rocket Pharmaceuticals

30/04/2024 12:39

* Rocket Pharmaceuticals Inc  RCKT.OQ   RCKT.O  is expected
to show no change in quarterly revenue when it reports 
results on May 2 (estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Rocket Pharmaceuticals
Inc is
for a loss of 68 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 1.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Rocket
Pharmaceuticals Inc is $49.00​, above​ its last closing price
of $21.85. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.77       -0.79      -0.64     Beat    18.6
 Sep. 30 2023  -0.78       -0.81      -0.75     Beat    7.2
 Jun. 30 2023  -0.79       -0.79      -0.82     Missed  -3.8​
 Mar. 31 2023  -0.86       -0.85      -0.73     Beat    14.3
 ​​Dec.        -0.79       -0.80      -0.92     Missed  -14.6
 31 2022                                                
 Jan. 1 0001   -0.80       -0.79      -0.87     Missed  -10.2​
 Jun. 30 2022  -0.66       -0.68      -0.83     Missed  -21.6
 Mar. 31 2022  -0.72       -0.71      -0.67     Beat    5.6
 This summary was machine generated April 30 at 11:39 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)